Glucose transporter 1 (SLC2A1) and vascular endothelial growth factor A (VEGFA) predict survival after resection of colorectal cancer liver metastasis

Annals of Surgery

Volumn 263, Issue 1, 2016, Pages 138-145

  Goos, Jeroen A C M ^a   De Cuba, Erienne M V ^a   Coupé, Veerle M H ^a   Diosdado, Begoña ^a   Delis Van Diemen, Pien M ^a   Karga, Cemile ^a   Beliën, Jeroen A M ^a   Menke Van Der Houven Van Oordt, C Willemien ^a   Geldof, Albert A ^a   Meijer, Gerrit A ^a   Hoekstra, Otto S ^a   Fijneman, Remond J A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; HIF1; Liver metastasis; Prognostic biomarker; SLC2A1; VEGFA

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN A; SLC2A1 PROTEIN, HUMAN; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER TISSUE; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL CANCER LIVER METASTASIS; COLORECTAL LIVER METASTASIS; COLORECTAL SURGERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER RESECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SYSTEMIC THERAPY; TISSUE MICROARRAY; TISSUE SECTION; TUMOR GROWTH; BIOSYNTHESIS; CHEMISTRY; COLORECTAL TUMOR; LIVER NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY;

COLORECTAL NEOPLASMS; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84953839832     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001109     Document Type: Article

References (66)

1. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg. 1979;189:496-502.
2. Leporrier J, Maurel J, Chiche L, et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465-474.
3. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375:1030-1047.
4. Spolverato G, Ejaz A, Azad N, et al. Surgery for colorectal liver metastases: the evolution of determining prognosis. World J Gastrointest Oncol. 2013;5:207-221.
5. Spelt L, Andersson B, Nilsson J, et al. Prognostic models for outcome following liver resection for colorectal cancer metastases: a systematic review. Eur J Surg Oncol. 2012;38:16-24.
6. Ruers TJM, Wiering B, Van Der Sijp JRM, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18) F-FDG PET: a randomized study. J Nucl Med. 2009;50:1036-1041.
7. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16:5928-5935.
8. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8:425-437.
9. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891-899.
10. Greijer AE, Delis-Van Diemen PM, Fijneman RJA, et al. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Arch. 2008;452:535-544.
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732.
12. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol. 2007;22:559-572.
13. De Wit M, Jimenez CR, Carvalho B, et al. Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut. 2012;61:855-864.
14. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res. 1996;2:1151-1154.
15. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34-40.
16. Shen Y, Arbman G, Olsson B, et al. Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Int J Biol Markers. 2011;26:166-172.
17. Wood SM, Wiesener MS, Yeates KM, et al. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of HIF-1alpha-dependent and -independent hypoxia-inducible gene expression. J Biol Chem. 1998;273:8360-8368.
18. Riedl CC, Akhurst T, Larson S, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48:771-775.
19. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9:677-684.
20. Giles RH, Lolkema MP, Snijckers CM, et al. Interplay between VHL (HIF1alpha and Wnt (beta-catenin pathways during colorectal tumorigenesis. Oncogene. 2006;25:3065-3070.
21. Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013;19:5051-5060.
22. Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94:1823-1832.
23. Asghar U, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer. 2010;9:274-281.
24. Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18:1004-1012.
25. Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to bevacizumabcontaining chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012;21:309-315.
26. Goos JACM, Coupe VMH, Diosdado B, et al. Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. Br J Cancer. 2013;109:2445-2452.
27. Goos JACM, Hiemstra AC, Coupe VMH, et al. Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. Br J Cancer. 2014;111:749-755.
28. Stichting FMWV. Code Goed Gebruik van lichaamsmateriaal 2011. 2011. Ref Type: Internet Communication. Available at: www.federa.org/code-goedgebruik. Accessed January 27, 2010.
29. Simon R, Mirlacher M, Sauter G. Tissue microarrays. Biotechniques. 2004;36:98-105.
30. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93:309-314.
31. Zlobec I, Steele R, Terracciano L, et al. Selecting immunohistochemical cutoff scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007;60:1112-1116.
32. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61:92-105.
33. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
34. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067-9072.
35. Richard DE, Berra E, Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun. 1999;266:718-722.
36. Furlan D, Sahnane N, Carnevali I, et al. Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas. Surg Oncol. 2007;16(suppl 1):S25-S27.
37. Beasley NJP, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002;62:2493-2497.
38. Rohwer N, Dame C, Haugstetter A, et al. Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NFkappaB. PLoS One. 2010;5:e12038.
39. Blancher C, Moore JW, Talks KL, et al. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 2000;60:7106-7113.
40. Weber DC, Tille JC, Combescure C, et al. The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediateand high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiat Oncol. 2012;7:66.
41. Fillies T, Werkmeister R, Van Diest PJ, et al. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer. 2005;5:84.
42. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF (VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55:4575-4580.
43. Garcia-Alfonso P, Grande E, Polo E, et al. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis. 2014;17:805-821.
44. Brogi E, Wu T, Namiki A, et al. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649-652.
45. Bruhn MA, Townsend AR, Khoon Lee C, et al. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. Int J Cancer. 2014;135:731-741.
46. Xue X, Taylor M, Anderson E, et al. Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res. 2012;72:2285-2293.
47. Imamura T, Kikuchi H, Herraiz MT, et al. HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer. 2009;124:763-771.
48. Knijn N, Mekenkamp LJM, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104:1020-1026.
49. Stange DE, Engel F, Longerich T, et al. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut. 2010;59:1236-1244.
50. Garcea G, Lloyd TD, Gescher A, et al. Angiogenesis of gastrointestinal tumours and their metastases-a target for intervention? Eur J Cancer. 2004;40:1302-1313.
51. Wali RK, Roy HK, Kim YL, et al. Increased microvascular blood content is an early event in colon carcinogenesis. Gut. 2005;54:654-660.
52. Mooteri S, Rubin D, Leurgans S, et al. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum. 1996;39:1073-1080.
53. Bendardaf R, Buhmeida A, Hilska M, et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term diseasespecific survival. Anticancer Res. 2008;28:3865-3870.
54. Hollingsworth SJ, Drye ER, Tou SIH, et al. Expression of angiogenic VEGF-A (soluble isoforms 121, 165) and lymphangiogenic VEGF-C in colorectal cancers with micro-satellite instability. J Surg Oncol. 2005;92:317-325.
55. Lynch HT, De La Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999;36:801-818.
56. Haddad R, Ogilvie RT, Croitoru M, et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncol. 2004;11:977-982.
57. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia. 2006;20:385-391.
58. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741-4751.
59. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106:13820-13825.
60. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
61. Lindeman GJ, Visvader JE. Insights into the cell of origin in breast cancer and breast cancer stem cells. Asia Pac J Clin Oncol. 2010;6:89-97.
62. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217-227.
63. Pohl M, Werner N, Munding J, et al. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol. 2011;49:1398-1406.
64. Kubota R, Kubota K, Yamada S, et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104-112.
65. Gil-Bernabe AM, Ferjancic S, Tlalka M, et al. Recruitment of monocytes (-macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood. 2012;119:3164-3175.
66. Bos R, Van Der Hoeven JJM, Van Der Wall E, et al. Biologic correlates of (18) fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.